Full analysis of multinational pivotal study results of golidocitinib in relapsed or refractory peripheral T-cell lymphoma (r/r PTCL) (JACKPOT8 PART B) simultaneously published in The Lancet Oncology and presented in oral session at the 65th American Society of Hematology Annual Meeting and Exposition (2023 ASH, San Diego). Golidocitinib demonstrated superior and durable clinical benefits in the treatment of r/r PTCL, with a median duration of response (mDoR) of 20.7 months, significantly outperforming existing treatment options.

SHANGHAI, Dec. 10, 2023 /PRNewswire/ — Dizal today presented the full analysis of the multinational pivotal study of golidocitinib for r/r PTCL (JACKPOT8 PART B) in an oral presentation at the 65th American Society of Hematology Annual Meeting and Exposition (2023 ASH, San Diego). The results were simultaneously published in the prestigious peer-reviewed journal The Lancet Oncology (Impact Factor: 54.4). This follows the publication of the Phase I clinical data of golidocitinib for the treatment of r/r PTCL (JACKPOT8 PART A) in Annals of Oncology (Impact Factor: 51.8) three months ago.

Golidocitinib is currently the first and only Janus kinase 1 (JAK1) selective inhibitor being evaluated for the treatment of r/r PTCL. A total of 104 patients with r/r PTCL were enrolled in the JACKPOT8 PART B study to evaluate the efficacy and safety of golidocitinib as a monotherapy. At the cut-off date of August 31, 2023, per independent review committee (IRC) assessment, 70% of patients achieved target lesion size reduction, yielding an overall response rate (ORR) of 44.3%, and a complete response rate (CRR) of 23.9%. Tumor responses were observed across various PTCL subtypes. The responses were durable, with the median duration of response (mDoR) of 20.7 months. The median progression-free survival (mPFS) was 5.6 months, and the median overall survival (mOS) was 19.4 months and still ongoing. As a potent JAK1 inhibitor with > 200 to 400-fold selectivity over other JAK family members, golidocitinib demonstrated a favorable safety profile. The most common treatment-related adverse events (TRAEs) were reversible and clinically manageable. These findings highlight the potential of golidocitinib to offer robust and durable clinical benefits for patients with r/r PTCL.

"PTCL is a highly heterogeneous and aggressive non-Hodgkin lymphoma (NHL) with the characteristics of various subtypes, high recurrence rate and poor prognosis. Patients with r/r PTCL have limited treatment options and a poor prognosis with a low survival rate. The efficacy of current treatment modalities varies among different r/r PTCL subtypes." said Jun Zhu, MD, PhD at the Department of Lymphoma, Peking University Cancer Hospital and Institute, the correspondence author of the paper, "The JAK/STAT signaling pathway plays a pivotal role in the pathogenesis and progression of various hematologic malignancies, including T-cell malignancies. Consequently, targeting the JAK/STAT pathway emerges as an innovative and highly promising treatment option for PTCL. Golidocitinib is an oral, potent, JAK1 only inhibitor with superior selectivity and favorable pharmacokinetic properties, offers robust and sustained inhibition of the JAK/STAT pathway while maintaining optimal clinical safety."

"In the JACKPOT8 PART B study, more than 100 patients with r/r PTCL were enrolled. The efficacy analysis of 88 patients revealed an ORR of 44.3%, with 23.9% achieving complete response. Notably, a consistently high ORR was observed across various PTCL subtypes. The median DoR for golidocitinib was 20.7 months, mPFS reached 5.6 months, and mOS was 19.4 months." said Yuqing Song, MD, PhD at the Department of Lympho-Oncology of Peking University Cancer Hospital, the lead author of the paper, "Golidocitinib demonstrates superior ORR and survival results as compared to the current available treatment options and offers hope for improving the poor prognosis of patients with r/r PTCL. These findings present innovative therapeutic possibilities and paves the way towards better patient outcomes."

"It is gratifying to see the increasing recognition of golidocitinib’s potential as a new therapy for patients with PTCL." said Xiaolin Zhang, Ph.D., Chairman and CEO of Dizal, "Patients with r/r PTCL have long been facing limited treatment options and a poor prognosis. Golidocitinib stands as a major achievement resulting from Dizal’s dedicated translational science efforts. Its superior efficacy and safety, as demonstrated through compelling global pivotal trials, bring hope for these underserved patients."

These findings, highlighting the superior efficacy and safety of golidocitinib, have been widely acknowledged at prestigious conferences including ASCO, EHA, ICML, and ASH, with six oral presentations over four consecutive years. In September 2023, the NDA for golidocitinib was accepted by the CDE with Priority Review status for the treatment of r/r PTCL. Dizal continues to expand the scope of clinical research on golidocitinib and explore its application in a broader patient population. At 2023 ASH, Dizal will also announce positive results of golidocitinib as maintenance therapy for patients with PTCL after first-line systemic therapy in a phase 2 study (JACKPOT26).

About golidocitinib (DZD4205)

Golidocitinib is currently the first and only Janus kinase 1 (JAK1) selective inhibitor being evaluated for the treatment of r/r PTCLs. At the data cut-off date of August 31, 2023, Golidocitinib has demonstrated robust and durable anti-tumor activity, with an ORR of 44.3%. More than 50% of the patients with tumor remission achieved a complete response with a CRR of 23.9%. Per IRC assessment, mDoR reached 20.7 months. Golidocitinib was granted Fast Track Designation by the U.S. FDA for the treatment of r/r PTCL in February 2022. In September 2023, the CDE accepted the NDA and granted the Priority Review status for the treatment of r/r PTCL. The Phase I clinical data of golidocitinib for the treatment of r/r PTCL (JACKPOT8 PART A) was published in Annals of Oncology (Impact Factor: 51.8), and global pivotal trials data of golidocitinib for the treatment of r/r PTCL (JACKPOT PART B) was published in The Lancet Oncology (Impact Factor: 54.4).

About Dizal

Dizal is a biopharmaceutical company, dedicated to the discovery, development and commercialization of differentiated therapeutics for the treatment of cancer and immunological diseases. The company aims to develop first-in-class and groundbreaking new medicines, and further address unmet medical needs around the world. Deep-rooted in translational science and molecular design, it has established an internationally competitive portfolio of five clinical-stage assets with two leading assets in global pivotal studies and one already launched.

To learn more about Dizal, please visit www.dizalpharma.com, or follow us at Linkedin or Twitter.

Forward-Looking Statements

This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words "anticipate", "believe", "estimate", "expect", and "intend" and similar expressions, as they relate to Dizal, are intended to identify certain forward-looking statements. Dizal does not intend to update these forward-looking statements regularly.

These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections, and understandings of the management of Dizal with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties, and other factors, some of which are beyond Dizal’s control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, Dizal’s competitive environment, and political, economic, legal, and social conditions.

Dizal, the Directors, and the employees of Dizal assume (a) no obligation to correct or update the forward-looking statements contained on this site; and (b) no liability in the event that any of the forward-looking statements does not materialize or turnout to be incorrect.

Source : Dizal's Golidocitinib Pivotal Trial Demonstrates Superior and Durable Clinical Benefits for Patients with r/r PTCL in Oral Presentation at 2023 ASH

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

Gaabor will Launch New Products on December 12

CISION PR Newswire

Dec 10, 2023

HO CHI MINH CITY, Vietnam, Dec. 10, 2023 /PRNewswire/ — Gaabor kitchen appliances brand, as one of the leading retailers of the online market of small household electrical appliances. Many incentives and attractive promotions took place in the last year and Gaabor’s most exciting incentive programs has returned at the end of the year.

Only on December 12, Gaabor will provide everyone with new products are high quality with super attractive prices. GH-M13 will be the best assistant for preparing delicious and healthy food with 1.7L capacity hot pot, suitable for 2-3 people. One knob to turn on immediately and control the heating temperature.

Say goodbye to the hassle of cords and enjoy thorough cleaning with VCF8T-WH01A at up to 15600mAh battery up to 30 minutes of runtime. You can clean house in one step using the best vacuum and mop combo devices. Cleaning up messes and eliminating dirt and dust quick and easy. They are suitable for the cleanup activities at the end of the year.

Especially, model is the most expected of Gaabor will appear at the event – GA-M6A with a capacity of 6L, 8 customizable programs for one-touch. With higher power 1700W for healthier eating and faster cooking results. With more than 20.000 orders on e-commerce platforms and 4.9 stars rating.

The "Super Sale Party" will occur from 12.12 – 14.12. Especially on December 12, a series of appealing deals up to 50% off, valuable vouchers, exclusive offers, destruction deals, flash sales, and lucky gifts will be launched by the collaboration of Gaabor and Shopee.

Take note of this chance to enjoy this 12.12 pinnacle shopping season. Visit Shopee, Lazada, Tiktok, Tiki, get the best deals.

Source : Gaabor will Launch New Products on December 12

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

US, Philippines Condemn Chinese Coast Guard’s ‘High-Seas Assault’

voanews

Dec 10, 2023

US, Philippines Condemn Chinese Coast Guard's 'High-Seas Assault'

The Philippine and the United States condemned the Chinese coast guard’s assault and harm to three Filipino fisheries vessels near the disputed Scarborough Shoal in the South China Sea.

The Philippines and the United States have both condemned a high-seas attack by the Chinese coast guard and suspected militia ships in the disputed Scarborough Shoal in the South China Sea. This attack caused “significant damage” to the navigation equipment of one of the three Bureau of Fisheries and Aquatic Resources ships and also caused “severe temporary discomfort and incapacitation” to some Filipino crew. The Philippines and China have had territorial disputes in the South China Sea due to conflicting claims.

The Philippines government has demanded that China stop its aggressive activities and uphold international law, while the U.S. Ambassador to Manila condemned China’s actions as “aggressive” and “illegal.” The Chinese coast guard defended its actions, claiming they were implemented in line with the law, and deployed personnel to drive away Filipino fishermen.

The Philippines has allowed a larger U.S. military presence in their military bases to strengthen territorial defense amid China’s aggressive actions in the disputed waters. The Philippines has also launched joint sea and air patrols with the U.S. and Australia.

Source : US, Philippines Condemn Chinese Coast Guard’s ‘High-Seas Assault’

Global Incubation Innovation Forces Gather in Lingang for World Top-Performing Incubator Forum 2023

CISION PR Newswire

Dec 10, 2023

SHANGHAI, Dec. 10, 2023 /PRNewswire/ — From December 5th to 6th, World Top-Performing Incubator Forum 2023 with the theme of "Innovation Incubates the Future" was held in Lingang New Area. Chen Jinshan, member of the Standing Committee of the CPC Shanghai Municipal Committee, Secretary of Party Working Committee of Lingang New Area, Director of Lingang Special Area Administration expressed during the opening ceremony that Lingang New Area is promoting the leadership of scientific and technological innovation, attracting top incubation institutions, venture capitals, and other global sci-tech resources, deepening high-level technological innovation incubation and cooperation, and accelerating the development of "City of Innovation and Entrepreneurship".

Yuan Guohua, Deputy Secretary of the Party Working Committee of Lingang New Area, Secretary of the Party Committee, and Chairman of Lingang Group, Zhao Jian, Chief Engineer of the Shanghai Science and Technology Commission, Xi Lifeng, Member of the CPC SJTU Standing Committee, and Vice President of Shanghai Jiao Tong University, Xu Tian, Genetics Chair Professor and Vice President at Westlake University, Ali Amin, Co-founder and CEO of UBI Global inaugurated this forum.

Wu Xiaohua, Deputy Secretary of Party Working Committee of Lingang New Area Administration and First-class Inspector of Lingang New Area, and Weng Kaining, Deputy Secretary of Party Committee and President of Lingang Group, along with leaders from top incubators, such as Lingang Science and Technology Investment, MiraclePlus Shanghai Alumni Center, ATLATL Center for Innovation & Research, PNP China, XNode, SIMIC InnoSpring, Casstar, AMl (Advanced Materials Incubator),Step Fund,P4 Precision Medicine Accelerator,CodeBase and Start-UpChile, jointly established the "International Innovation Synergy and Incubation Alliance" and released the "Cooperation Initiative of International Innovation Synergy and Incubation Alliance" to issue initiatives and proposals to all talents around the world.

SYNLINX launched its brand and contracted with its first settled enterprises and partners. "SYNLINX Semiconductor" and "SYNLINX Life Science and Technology" are established to empower the technology start-ups.

The First Batch of Proof-of-Concept Center for Frontier Technology released its First Group projects.Abundant top-level resources of both SJTU and Lingang Group are integrated to build a futuristic proof-of-concept center for frontier industrial technologies.

At the opening ceremony, Frederico Lourenco from Flagship Pioneering, Ali Amin from UBI Global,Handson Gilford from The Foundry, Xi Lifeng from SJTU and Xu Tian from Westlake University delivered keynote speeches one by one.

At the panel themed "Innovation Models and Challenges for Global Incubators", panelists believed that incubators, as a crucial innovation support system, have gained worldwide attention and application.

Furthermore, the specialized seminar "A Deep Dive into Key Metrics for Success","Innovation Incubation and Investment by Large Enterprises", "Capital Empowers Incubation for Life Science Industry" and "New Model for Advanced Incubation" were conducted.

This forum is hosted by Lingang Special Area of China (Shanghai) Pilot Free Trade Zone Administration, Science and Technology Commission of Shanghai Municipality and Shanghai Lingang Economic Development (Group) Co.,Ltd,organized by Shanghai Technology Innovation Center, Shanghai Lingang Economic Development Group Technology Investment Co., Ltd, Stepholdings Co., Ltd, Co organized by Shanghai Business Incubation Association (STBIA).

Source : Global Incubation Innovation Forces Gather in Lingang for World Top-Performing Incubator Forum 2023

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

GLOBALLY RECOGNIZED ROSEN LAW FIRM Encourages Barclays PLC Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – BCS, BCLYF

Corporate News Media OutReach

Dec 10, 2023

Hong Kong Baptist University-led research discovers new therapeutic target for irritable bowel syndrome

New York, New York – Newsfile Corp. – December 9, 2023 – WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Barclays PLC (NYSE: BCS) (OTC Pink: BCLYF) between July 22, 2019 and October 12, 2023, both dates inclusive (the “Class Period”), of the important January 2, 2024 lead plaintiff deadline in the securities class action commenced by the Firm.

SO WHAT: If you purchased Barclays securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Barclays class action, go to https://rosenlegal.com/submit-form/?case_id=19796 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than January 2, 2024. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period defendants made materially false and/or misleading statements and/or failed to disclose that: (1) contrary to false public assertions, Barclays’s now-former group chief executive James “Jes” Staley (“Staley”) had a very close relationship with Jeffrey Epstein (“Epstein”); (2) Staley was reportedly aware of Epstein’s criminal activities and may have even sexually assaulted a victim who had previously been trafficked by Epstein; (3) Staley’s close, personal relationship with Epstein, and potential criminal activity, if discovered, could bring reputational, legal, and financial harm to Barclays; (4) as a result, Barclays’s response to the British Financial Conduct Authority’s (“FCA”) inquiry regarding Staley’s relationship with Epstein was materially false; (5) Barclays, having become aware of information contradicting its response to the FCA’s inquiry, then failed to update the response so that it would be accurate, or otherwise take any meaningful action; and (6) as a result, defendants’ statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Barclays class action, go to https://rosenlegal.com/submit-form/?case_id=19796 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm.

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm’s attorneys are ranked and recognized by numerous independent and respected sources. Rosen Law Firm has secured hundreds of millions of dollars for investors.

Attorney Advertising. Prior results do not guarantee a similar outcome.

——————————-

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40^th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
[email protected]
[email protected]
www.rosenlegal.com

The issuer is solely responsible for the content of this announcement.

Source link

This content was prepared by Media OutReach. The opinions expressed in this article are the author's own and do not reflect the view of Siam News Network.

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Brainstorm Cell Therapeutics Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – BCLI

Corporate News Media OutReach

Dec 10, 2023

New York, New York – Newsfile Corp. – December 9, 2023 – WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI) between August 15, 2022 and September 27, 2023, both dates inclusive (the “Class Period”), of the important January 2, 2024 lead plaintiff deadline in the securities class action commenced by the Firm.

SO WHAT: If you purchased Brainstorm Cell securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Brainstorm Cell class action, go to https://rosenlegal.com/submit-form/?case_id=19375 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than January 2, 2024. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period defendants made materially false and/or misleading statements and/or failed to disclose that: (1) Brainstorm Cell downplayed the severity of the U.S. Food and Drug Administration’s (“FDA”) refusal to file letter; (2) Brainstorm Cell continued to conceal the risks associated with the submission of the biologics license application (“BLA”); and (3) as a result, defendants’ statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Brainstorm Cell class action, go to https://rosenlegal.com/submit-form/?case_id=19375 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm.

Attorney Advertising. Prior results do not guarantee a similar outcome.

——————————-

Contact Information:

The issuer is solely responsible for the content of this announcement.

Source link

This content was prepared by Media OutReach. The opinions expressed in this article are the author's own and do not reflect the view of Siam News Network.

ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Blue Ridge Bankshares, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – BRBS

Corporate News Media OutReach

Dec 10, 2023

New York, New York – Newsfile Corp. – December 9, 2023 – WHY: Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of the securities of Blue Ridge Bankshares, Inc. (NYSE American: BRBS) between March 10, 2023 and October 31, 2023, both dates inclusive (the “Class Period”). A class action has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than February 5, 2024 in the securities class action first filed by the Firm.

SO WHAT: If you purchased Blue Ridge securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Blue Ridge class action, go to https://rosenlegal.com/submit-form/?case_id=20587 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than February 5, 2024. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants made materially false and/or misleading statements and/or failed to disclose that: (1) Blue Ridge Bankshares, Inc.’s financial statements from March 10, 2023 to the present included certain errors; (2) as a result, Blue Ridge Bankshares would need to restate its previously filed financial statements from March 10, 2023 to October 31, 2023; and (3) as a result, defendants’ statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Blue Ridge class action, go to https://rosenlegal.com/submit-form/?case_id=20587 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm.

Attorney Advertising. Prior results do not guarantee a similar outcome.

——————————-

Contact Information:

The issuer is solely responsible for the content of this announcement.

Source link

This content was prepared by Media OutReach. The opinions expressed in this article are the author's own and do not reflect the view of Siam News Network.

ROSEN, A RANKED AND LEADING FIRM, Encourages ACELYRIN, INC. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – SLRN

Corporate News Media OutReach

Dec 10, 2023

New York, New York – Newsfile Corp. – December 9, 2023 – WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ACELYRIN, INC. (NASDAQ: SLRN) between May 4, 2023 and September 11, 2023, both dates inclusive (the “Class Period”), of the important January 16, 2024 lead plaintiff deadline.

SO WHAT: If you purchased ACELYRIN securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the ACELYRIN class action, go to https://rosenlegal.com/submit-form/?case_id=20478 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than January 16, 2024. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants made false and/or misleading statements and/or failed to disclose that: (1) izokibep was less effective in treating Hidradenitis Suppurativa (“HS”) than defendants had led investors to believe; (2) accordingly, ACELYRIN overstated izokibep’s clinical and/or commercial prospects; (3) as a result, ACELYRIN also overstated the Company’s business prospects post-IPO; and (4) as a result, the Company’s public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the ACELYRIN class action, go to https://rosenlegal.com/submit-form/?case_id=20478 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

——————————-

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
[email protected]
[email protected]
www.rosenlegal.com

The issuer is solely responsible for the content of this announcement.

Source link

This content was prepared by Media OutReach. The opinions expressed in this article are the author's own and do not reflect the view of Siam News Network.